PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that shareholders approved all proposals put forward by the Board of Directors at the Company’s fifth annual General Meeting (AGM 2026) with a large majority. The meeting took place at the Chollerhalle in Zug, with 26,780,855 shares represented, corresponding to 80.85% of the issued registered shares.
All six members of the Board of Directors proposed for re-election were appointed for a term ending at the conclusion of the next annual General Meeting 2027. Peter Wilden was re-elected as Chair of the Board of Directors, and Philippe Weber and Peter Wilden were each individually re-elected as members of the Remuneration and Nomination Committee for a term ending at the 2027 AGM.
Other approved proposals included the re-election of Statutory Auditors and the Independent Proxy, as well as the approval of the maximum aggregate compensation for the Board of Directors and Executive Committee. Shareholders granted discharge to all board and executive committee members for their activities in the financial year 2025. They also approved the Management Report, Statutory Financial Statements, Consolidated Financial Statements, and the report on non-financial matters for 2025, along with the Remuneration Report 2025 in a separate consultative vote.
The minutes of the AGM 2026 will be available within 15 days on the Company’s website. The next annual General Meeting 2027 will be held on 7 April 2027.
